N@N

CYTRX CORP (NASDAQ:CYTR), Down By 7.32% ($0.03) From $0.410 After BUYINS.NET Report Predicted Weakness Before Earnings

^{Published on 2011-08-05 07:21:49 - WOPRAI}
 

August 5, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Friday, August 5th 2011 stating that CYTRX CORP (NASDAQ:CYTR) was expected to be Down Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=cytr&id=183355

At the time this story was written, CYTRX CORP (NASDAQ:CYTR) is Down By 7.32% ($0.03) From $0.410 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

CYTRX CORP (NASDAQ:CYTR) - CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics, specializing in oncology. The companys drug development pipeline includes clinical development of three product candidates for cancer indications, including three planned Phase II clinical trials for INNO-206 as a treatment for pancreatic cancer, gastric (stomach) cancer, and soft tissue sarcomas; two Phase II proof-of-concept clinical trials with bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia and patients with glioblastoma multiforme; and a registration study of tamibarotene for the treatment of acute promyelocytic leukemia. It also has molecular chaperone regulation program, which includes a planned Phase II clinical study of arimoclomol in amyotrophic lateral sclerosis and Phase I stage development of Iroxanadine for various potential indications. The company was founded in 1985 and is headquartered in Los Angeles, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. CYTRX CORP (NASDAQ:CYTR) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net